RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:98843

Classic Hodgkin lymphoma, nodular sclerosis type

medium confidenceSubtype of disorder

Publications

3,778

95.4th percentile

Trials

15

Interventional, condition-specific

Researchers

1,260

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (13)

Hodgkin lymphoma, nodular sclerosis · Hodgkin's disease nodular sclerosis · Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality) · Hodgkin's disease, nodular sclerosis of unspecified site · Hodgkin's nodular sclerosis · NSCHL · NSHD · NSHL · nodular sclerosis Classic Hodgkin lymphoma · nodular sclerosis Hodgkin lymphoma · nodular sclerosis Hodgkin's disease · nodular sclerosis Hodgkin's lymphoma · nodular sclerosis classical Hodgkin lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3,778 matched papers (1,918 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    15 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

3,778

3,778 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

3,778 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,918 in the last 10 years · medium confidence · 95.4th percentile (publications denominator)

Phrase hits: 3,778 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,260

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hansmann ML4 papers · 2026

    Reference and Consultant Center of Lymph Node and Lymphoma Pathology at Dr. Senckenberg Institute for Pathology, Frankfurt/Main, Hessen, Germany.

    Papers in Europe PMC
  2. 02
    Liu Y4 papers · 2026

    Department of Hematology-Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.

    Papers in Europe PMC
  3. 03
    Medeiros LJ4 papers · 2026

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

    Papers in Europe PMC
  4. 04
    Nakamura S4 papers · 2023

    Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

    Papers in Europe PMC
  5. 05
    Satou A4 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  6. 06
    Takahara T4 papers · 2023

    Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

    Papers in Europe PMC
  7. 07
    Wurzel P4 papers · 2026

    Department of Molecular Bioinformatics, Johann Wolfgang Goethe-University Frankfurt/Main, Frankfurt/Main, Hessen, Germany.

    Papers in Europe PMC
  8. 08
    Zhang Q4 papers · 2025

    Department of Nuclear Medicine, Lu'an People's Hospital of Anhui Province, Lu'an, China.

    Papers in Europe PMC
  9. 09
    Chen Y3 papers · 2025

    Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.

    Papers in Europe PMC
  10. 10
    Dierickx D3 papers · 2025

    Department of Hematology, University Hospitals Leuven, Leuven, Belgium.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

15

interventional trials for this specific condition

15 interventional trials matched this specific condition name; none in our sample are currently recruiting. 43 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

15 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.5th percentile).

medium confidence · 93.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

15 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Broader category: classic Hodgkin lymphoma

43

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic Hodgkin lymphoma, nodular sclerosis type" OR "Hodgkin lymphoma, nodular sclerosis" OR "Hodgkin's disease nodular sclerosis" OR "Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality)" OR "Hodgkin's disease, nodular sclerosis of unspecified site" OR "Hodgkin's disease, nodular sclerosis of the unspecified site" OR "Hodgkin's nodular sclerosis" OR "NSCHL" OR "nodular sclerosis Classic Hodgkin lymphoma" OR "nodular sclerosis Hodgkin lymphoma" OR "nodular sclerosis Hodgkin's disease" OR "nodular sclerosis Hodgkin's lymphoma" OR "nodular sclerosis classical Hodgkin lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic Hodgkin lymphoma, nodular sclerosis type" OR "Hodgkin lymphoma, nodular sclerosis" OR "Hodgkin's disease nodular sclerosis" OR "Hodgkin's disease, nodular sclerosis NOS (morphologic abnormality)" OR "Hodgkin's disease, nodular sclerosis of unspecified site" OR "Hodgkin's disease, nodular sclerosis of the unspecified site" OR "Hodgkin's nodular sclerosis" OR "NSCHL" OR "nodular sclerosis Classic Hodgkin lymphoma" OR "nodular sclerosis Hodgkin lymphoma" OR "nodular sclerosis Hodgkin's disease" OR "nodular sclerosis Hodgkin's lymphoma" OR "nodular sclerosis classical Hodgkin lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 15 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"classic Hodgkin lymphoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: NSHD; NSHL

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:34:03.864Z